

David Wu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1307014/david-wu-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

1,914
citations

18
h-index

43
g-index

55
ext. papers

2,441
ext. citations

4.4
avg, IF

4.41
L-index

#	Paper	IF	Citations
52	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021 , 34, 1673-1685	9.8	5
51	De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 1092-1102	1.9	1
50	A Curriculum for Genomic Education of Molecular Genetic Pathology Fellows: A Report of the Association for Molecular Pathology Training and Education Committee. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 1218-1240	5.1	1
49	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. <i>Blood Advances</i> , 2020 , 4, 6039-6050	7.8	24
48	Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. <i>Clinical Chemistry</i> , 2020 , 66, 1379-1380	5.5	
47	How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for variant curation for germline predisposition to myeloid malignancies. <i>Haematologica</i> , 2020 , 105, 870-887	6.6	14
46	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). <i>Blood</i> , 2020 , 136, 23-23	2.2	
45	Flow cytometric features of incidental indolent T lymphoblastic proliferations. <i>Cytometry Part B - Clinical Cytometry</i> , 2020 , 98, 282-287	3.4	5
44	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2020 , 95, 1553-1561	7.1	9
43	Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , 2019 , 134, 1475-1475	2.2	1
42	Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade. <i>Blood</i> , 2019 , 134, 1493-1493	2.2	
41	Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas. <i>Methods in Molecular Biology</i> , 2019 , 1956, 35-60	1.4	3
40	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. <i>Blood Advances</i> , 2019 , 3, 2962-2979	7.8	55
39	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. <i>Blood Advances</i> , 2019 , 3, 4065-4080	7.8	38
38	Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1. <i>Cytometry Part B - Clinical Cytometry</i> , 2019 , 96, 67-72	3.4	14
37	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1615-1620	4.7	20
36	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018 , 131, 1350-1359	2.2	108

35	Ultrasensitive Detection of Chimerism by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing of Copy Number Deletion Polymorphisms. <i>Clinical Chemistry</i> , 2018 , 64, 938-949	5.5	2
34	A novel disease-causing synonymous exonic mutation in affecting RNA splicing. <i>Blood</i> , 2018 , 132, 1211-1215		17
33	Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment. <i>Blood</i> , 2018 , 132, 825-836	2.2	85
32	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 293-305	6.7	52
31	Pathology of Castleman Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018 , 32, 37-52	3.1	45
30	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. <i>British Journal of Haematology</i> , 2018 , 183, 601-607	4.5	6
29	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017 , 129, 1646-1657	2.2	234
28	Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. <i>Haematologica</i> , 2017 , 102, 1549-1557	6.6	19
27	Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication. <i>Journal of Virology</i> , 2017 , 91,	6.6	7
26	Targeted Next-Generation Sequencing of Acute Leukemia. <i>Methods in Molecular Biology</i> , 2017 , 1633, 163-184	1.4	3
25	Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2016 , 90, 424-32	3.4	12
24	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 380-385	4.7	28
23	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016 , 128, 1086-1086	2.2	2
22	Detection of Mutations in Inherited Bone Marrow Failure and Myelodysplastic Syndrome Genes Using Genomic Capture and Massively Parallel Sequencing in Clinical Diagnostics. <i>Blood</i> , 2016 , 128, 1507-1507		
21	Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 278-87	5	22
20	Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1667-70	3	5
19	Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression. <i>Angewandte Chemie</i> , 2016 , 128, 9121-9124	3.6	
18	Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression. <i>Angewandte Chemie - International Edition</i> , 2016 , 55, 8975-8	16.4	8

17	CADD score has limited clinical validity for the identification of pathogenic variants in noncoding regions in a hereditary cancer panel. <i>Genetics in Medicine</i> , 2016 , 18, 1269-1275	8.1	30
16	Clinical Experience With Modified, Single-Tube T-Cell Receptor VβFlow Cytometry Analysis for T-Cell Clonality. <i>American Journal of Clinical Pathology</i> , 2016 , 145, 467-85	1.9	9
15	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> , 2016 , 127, 2406-10	2.2	436
14	Jumping translocations in myelodysplastic syndromes. <i>Cancer Genetics</i> , 2016 , 209, 395-402	2.3	7
13	Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. <i>Cytometry Part B - Clinical Cytometry</i> , 2015 , 88, 58-63	3.4	12
12	Computer-aided detection of rare tumor populations in flow cytometry: an example with classic Hodgkin lymphoma. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 517-24	1.9	3
11	Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 1972-1972 ²	2.2	
10	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 56-67	5.1	203
9	Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. <i>Clinical Cancer Research</i> , 2014 , 20, 4540-8	12.9	110
8	Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. <i>Cytometry Part B - Clinical Cytometry</i> , 2014 ,	3.4	14
7	Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. <i>Modern Pathology</i> , 2014 , 27, 1438-46	9.8	45
6	Flow cytometry for non-Hodgkin and classical Hodgkin lymphoma. <i>Methods in Molecular Biology</i> , 2013 , 971, 27-47	1.4	17
5	Cutaneous T-cell lymphoma in sub-Saharan Africa. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 275-280	7.3	6
4	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. <i>Blood</i> , 2013 , 122, 2550-2550	2.2	1
3	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. <i>Blood</i> , 2013 , 122, 1341-1341	2.2	
2	Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm. <i>Blood</i> , 2013 , 122, 2614-2614	2.2	
1	High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. <i>Science Translational Medicine</i> , 2012 , 4, 134ra63	17.5	175